Ananthakrishnan A, Luz ACG, Kc S, Ong L, Oh C, et al. How can health technology assessment support our response to public health emergencies? Health Res Policy Syst. 2022;20(1):124.

Article  PubMed  PubMed Central  Google Scholar 

EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines. European Medicines Agency (EMA); [30-06-2022]. Retrieved from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/guidance-developers-companies/covid-19-guidance-evaluation-marketing-authorisation.

Communication from the commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions EU Strategy on COVID-19 Therapeutics. Brussels: European Commission, Directorate-General for Health and Food Safety; 2021 [19-07-2023]. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A52021DC0355&qid=1689771395875.

Cohen J, Kupferschmidt K. The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug. [19-07-2023]. https://www.science.org/content/article/very-very-bad-look-remdesivir-first-fda-approved-covid-19-drug.

Elvidge J, Dawoud D. Assessing technologies for COVID-19: What are the challenges for health technology assessment agencies? Findings From a survey and roundtable workshop. Pharmacoeconomics. 2021;39(12):1455–63.

Article  PubMed  PubMed Central  Google Scholar 

Elvidge J, Summerfield A, Knies S, Németh B, Kaló Z, et al. Health technology assessment of tests for SARS-CoV-2 and treatments for COVID-19: a proposed approach and best-practice recommendations. Int J Technol Assess Health Care. 2023;39(1): e24.

Article  PubMed  Google Scholar 

Vandepitte S, Alleman T, Nopens I, Baetens J, Coenen S, et al. Cost-effectiveness of COVID-19 policy measures: a systematic review. Value Health. 2021;24(11):1551–69.

Article  PubMed  PubMed Central  Google Scholar 

Elvidge J, Summerfield A, Nicholls D, Dawoud D. Diagnostics and treatments of COVID-19: a living systematic review of economic evaluations. Value Health. 2022;25(5):773–84.

Article  PubMed  PubMed Central  Google Scholar 

Rasmussen MK, Kronborg C, Fasterholdt I, Kidholm K. Economic evaluations of interventions against viral pandemics: a scoping review. Public Health. 2022;208:72–9.

Article  CAS  PubMed  Google Scholar 

Schallner N, Lieberum J, Kalbhenn J, Bürkle H, Daumann F. Intensive care unit resources and patient-centred outcomes in severe COVID-19: a prospective single-centre economic evaluation. Anaesthesia. 2022;77(12):1336–45.

Article  CAS  PubMed  Google Scholar 

Kairu A, Were V, Isaaka L, Agweyu A, Aketch S, et al. Modelling the cost-effectiveness of essential and advanced critical care for COVID-19 patients in Kenya. BMJ Glob Health. 2021;6(12): e007168.

Article  PubMed  Google Scholar 

Atherly AJ, van den Broek-Altenburg EM. The effect of medical innovation on the cost-effectiveness of COVID 19-related policies in the United States using a SIR model. BMC Health Serv Res. 2023;23(1):372.

Article  PubMed  PubMed Central  Google Scholar 

Li T, Guo Y. Optimal control and cost-effectiveness analysis of a new COVID-19 model for Omicron strain. Physica A. 2022;606: 128134.

Article  PubMed  PubMed Central  Google Scholar 

Gibson S, Saunders R, Stasko N, Bickerstaff C-B, Oakley J, et al. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19. J Med Econ. 2022;25(1):503–14.

Article  PubMed  Google Scholar 

Kilcoyne A, Jordan E, Thomas K, Pepper AN, Zhou A, et al. Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with coronavirus disease 19 (COVID-19) from the perspective of National Health Service England. ClinicoEcono Outcomes Res. 2022;14:231–47.

Article  Google Scholar 

Kilcoyne A, Jordan E, Zhou A, Thomas K, Pepper AN, et al. Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective. J Med Econ. 2022;25(1):160–71.

Article  PubMed  Google Scholar 

Lau VI, Fowler R, Pinto R, Tremblay A, Borgia S, et al. Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial. CMAJ Open. 2022;10(3):E807–17.

Article  PubMed  PubMed Central  Google Scholar 

Al-Qubbanchi FB, Al-Hamadani FY. A pharmacoeconomics study for anticoagulants used for hospitalized COVID-19 patients in Al-Najaf Al-Ashraf city—Iraq. Iraqi J Pharm Sci. 2022;30:48–59.

Google Scholar 

Rusdi SM, Yusvina, Dillasamola D, Efendi MR. Cost-effectiveness analysis of COVID-19 treatment for hospitalized patients: a healthcare provider perspective in Batam, Indonesia. J Public Health Dev 2023; 21(2).

Mills FP, Reis G, Wilson LA, Thorlund K, Forrest JI, et al. Early treatment with fluvoxamine among patients with COVID-19: a cost-consequence model. Am J Trop Med Hyg. 2023;108(1):101–6.

Article  CAS  PubMed  Google Scholar 

González-Castro A, Cuenca Fito E, Fernandez A, Peñasco Y, Modesto IAV, et al. Cost-effectiveness analysis high flow oxygen therapy in the treatment of SARS-CoV-2 pneumonia. J Healthc Qual Res. 2023;38(3):152–7.

Article  PubMed  Google Scholar 

Yeung K, Whittington MD, Beinfeld M, Mohammed R, Wright A, et al. Special assessment of outpatient treatments for COVID-19; final evidence report and meeting summary. Institute for Clinical and Economic Review. https://icer.org/assessment/covid-19-2022/.

Beinfeld M, Yeung K, Whittington MD, Mohammed R, Nhan E, et al. Oral treatments for outpatient COVID-19: effectiveness and value. J Manag Care Spec Pharm. 2022;28(8):903–9.

PubMed  Google Scholar 

Oksuz E, Malhan S, Gonen MS, Kutlubay Z, Keskindemirci Y, et al. Cost-effectiveness analysis of remdesivir treatment in COVID-19 patients requiring low-flow oxygen therapy: payer perspective in Turkey. Adv Ther. 2021;38(9):4935–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chow R, Simone CB II, Prsic EH, Shin HJ. Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients. Ann Palliat Med. 2022;11(7):2285–90.

Article  PubMed  Google Scholar 

Goswami H, Alsumali A, Jiang Y, Schindler M, Duke ER, et al. Cost-effectiveness analysis of molnupiravir versus best supportive care for the treatment of outpatient COVID-19 in adults in the US. Pharmacoeconomics. 2022;40(7):699–714.

Article  PubMed  PubMed Central  Google Scholar 

Rattanavipapong W, Poonsiri C, Isaranuwatchai W, Iamsirithaworn S, Apakupakul J, et al. Economic evaluation of evusheld for preexposure prevention of COVID-19 in high-risk populations: early evidence from Thailand. Appl Health Econ Health Policy. 2023;21(3):511–22.

Article  PubMed  PubMed Central  Google Scholar 

Carta A, Conversano C. Cost utility analysis of remdesivir and dexamethasone treatment for hospitalised COVID-19 patients—a hypothetical study. BMC Health Serv Res. 2021;21(1):986.

Article  PubMed  PubMed Central  Google Scholar 

Jovanoski N, Kuznik A, Becker U, Hussein M, Briggs A. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. J Manag Care Spec Pharm. 2022;28(5):555–65.

PubMed  Google Scholar 

Kelton K, Klein T, Murphy D, Belger M, Hille E, et al. Cost-effectiveness of combination of baricitinib and remdesivir in hospitalized patients with COVID-19 in the United States: a modelling study. Adv Ther. 2022;39(1):562–82.

Article  CAS  PubMed  Google Scholar 

Rafia R, Martyn-St James M, Harnan S, Metry A, Hamilton J, et al. A cost-effectiveness analysis of remdesivir for the treatment of hospitalized patients with COVID-19 in England and Wales. Value Health. 2022;25(5):761–9.

Article  PubMed  PubMed Central  Google Scholar 

Sheinson D, Dang J, Shah A, Meng Y, Elsea D, et al. A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther. 2021;38(4):1811–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whittington MD, Pearson SD, Rind DM, Campbell JD. The cost-effectiveness of remdesivir for hospitalized patients with COVID-19. Value Health. 2022;25(5):744–50.

Article  PubMed  PubMed Central  Google Scholar 

Águas R, Mahdi A, Shretta R, Horby P, Landray M, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun. 2021;12(1):915.

Article  PubMed  PubMed Central  Google Scholar 

Ohsfeldt R, Kelton K, Klein T, Belger M, Mc Collam PL, et al. Cost-effectiveness of baricitinib compared with standard of care: a modeling study in hospitalized patients with COVID-19 in the United States. Clin Ther. 2021;43(11):1877-93.e4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggeri M, Signorini A, Caravaggio S. Casirivimab and imdevimab: cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with COVID-19. PLoS ONE. 2023;18(2): e0279022.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggeri M, Signorini A, Caravaggio S, Rua J, Luís N, et al. Estimation model for healthcare costs and intensive care units access for covid-19 patients and evaluation of the effects of remdesivir in the Portuguese Context: hypothetical study. Clin Drug Investig. 2022;42(4):345–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jo Y, Jamieson L, Edoka I, Long L, Silal S, et al. Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa. Open Forum Infect Dis. 2021;8(3): ofab040.

Article  PubMed  PubMed Central  Google Scholar 

Congly SE, Varughese RA, Brown CE, Clement FM, Saxinger L. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Sci Rep. 2021;11(1):17787.

Article  CAS  PubMed  PubMed Central